Thomas Wilder joins Endologix's board
This article was originally published in Clinica
Stent graft developer Endologix has appointed Thomas Wilder to its board of directors. Mr Wilder is currently president and CEO of Sequent Medical, a privately-held company that is developing devices for neurovascular disease. He was previously president and CEO of PhotoThera, which is developing transcranial laser therapy for acute ischaemic stroke. Before this, he held similar roles at neurovascular specialist Micro Therapeutics, which was acquired by ev3 in January 2006. He also worked for Medtronic for 11 years in various roles. Mr Wilder replaces Paul McCormick, whose term on the board expired this month.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.